Chimeric antigen receptor T-cell therapy remains effective after exposure to bispecific antibodies. Comment to "Sequencing of cellular therapy and bispecific antibodies for the management of diffuse large B-cell lymphoma".
No abstract available
References:
Melody M, Gordon LI. Sequencing of cellular therapy and bispecific antibodies for the management of diffuse large B-cell lymphoma. Haematologica. 2024;109(10):3138-3145.
Crochet G, Iacoboni G, Couturier A, et al. . Efficacy of CAR T-cell therapy is not impaired by previous bispecific antibody treatment in large B-cell lymphoma. Blood. 2024;144(3):334-338.
Philipp N, Kazerani M, Nicholls A, et al. . T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals. Blood. 2022;140(10):1104-1118.